262,885 Shares in Tandem Diabetes Care, Inc. $TNDM Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 262,885 shares of the medical device company’s stock, valued at approximately $5,778,000. Tandem Diabetes Care accounts for about 1.4% of Lisanti Capital Growth LLC’s investment portfolio, making the stock its 20th biggest position.

Other large investors have also bought and sold shares of the company. Caitong International Asset Management Co. Ltd raised its position in Tandem Diabetes Care by 200.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,205 shares of the medical device company’s stock worth $27,000 after purchasing an additional 1,470 shares during the last quarter. Creative Financial Designs Inc. ADV raised its position in Tandem Diabetes Care by 36.0% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 3,431 shares of the medical device company’s stock worth $75,000 after purchasing an additional 909 shares during the last quarter. Farther Finance Advisors LLC raised its position in Tandem Diabetes Care by 36.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,600 shares of the medical device company’s stock worth $79,000 after purchasing an additional 965 shares during the last quarter. Quarry LP raised its position in Tandem Diabetes Care by 2,597.1% during the 3rd quarter. Quarry LP now owns 3,695 shares of the medical device company’s stock worth $45,000 after purchasing an additional 3,558 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Tandem Diabetes Care by 308.1% during the 4th quarter. GAMMA Investing LLC now owns 4,542 shares of the medical device company’s stock worth $100,000 after purchasing an additional 3,429 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on TNDM shares. Bank of America lowered their price objective on Tandem Diabetes Care from $35.00 to $25.00 and set a “neutral” rating for the company in a research report on Monday, May 18th. Weiss Ratings lowered Tandem Diabetes Care from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. Mizuho set a $24.00 price objective on Tandem Diabetes Care in a research report on Friday, May 8th. Lake Street Capital raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $50.00 price objective for the company in a research report on Monday, February 23rd. Finally, Stifel Nicolaus lifted their price objective on Tandem Diabetes Care from $20.00 to $22.00 and gave the stock a “hold” rating in a research report on Friday, February 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $29.63.

Tandem Diabetes Care Stock Performance

TNDM stock opened at $14.97 on Friday. The stock has a 50-day moving average price of $19.34 and a 200-day moving average price of $20.26. Tandem Diabetes Care, Inc. has a 1-year low of $9.98 and a 1-year high of $29.65. The company has a current ratio of 3.58, a quick ratio of 3.07 and a debt-to-equity ratio of 4.54. The firm has a market cap of $1.03 billion, a PE ratio of -10.69 and a beta of 1.64.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.16. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.The firm had revenue of $247.22 million during the quarter, compared to analyst estimates of $240.41 million. During the same period last year, the company posted ($0.66) EPS. The business’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, equities research analysts expect that Tandem Diabetes Care, Inc. will post -0.79 earnings per share for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.